Peter C. Fineran

This study uses CRISPRi screening in Mycobacterium tuberculosis to identify synergistic drug targets, finding that genetic interactions predict drug-drug synergies and identifying Pks13 as a key synergistic generalist.

This study compares CRISPR-Cas systems for RNA knockdown in rat sensory neurons, finding hfCas13d provides robust gene silencing with minimal toxicity.

The paper identifies structured RNA motifs and Aca proteins that regulate anti-CRISPR gene expression in bacteriophages, revealing new regulatory mechanisms beyond DNA-binding HTH regulators.

This paper identifies viral single-guide RNAs (vsgRNAs) that subvert bacterial CRISPR-Cas9 immunity by sequestering Cas9 and redirecting its activity, and shows they can enable genome editing in mammalian cells.

This study identifies antitoxin-induced auto-phosphorylation as the mechanism by which AbiEii toxin is neutralized, reclassifying Abi systems as Type VII toxin-antitoxin systems.

This study uses transposon mutagenesis and deep sequencing to identify essential genes in diverse phages and enables rapid genetic engineering of phage genomes.

The paper examines defence system abundances in microbial communities, finding environmental and viral density effects on their prevalence.

The paper shows internal translation of large subunit transcripts generates small subunits in type I CRISPR-Cas complexes, revealing widespread coding potential within cas genes.